Skip to main content
main-content

Medication and diabetic complications

medwireNews top story

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

Pills arranged as kidneys

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

medwireNews top story

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Kidneys

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

Featured podcast

EASD 2020: Editorial Board conference highlights

Sanjay Kalra, Lori Berard, John Wilding

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting (39:05). 

EASD 2020

DAPA-CKD trial: Renal benefits of SGLT2 inhibition in people with and without diabetes

Hiddo Heerspink

DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).

EASD 2020 News

Further VERTIS-CV analysis supports ertugliflozin renal benefits

Heart kidney and nerves

The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.

medwireNews top story

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

Flatline alert_heart monitor

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

medwireNews top story

DAPA-CKD shows dapagliflozin benefits regardless of diabetes

Kidneys

The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.

medwireNews top story

Dual targets difficult to reach in type 1 diabetes

Female archer aiming at target

People with type 1 diabetes treated with multiple daily insulin injections struggle to achieve guideline-recommended targets for time in hypoglycemia while simultaneously reaching their glycated hemoglobin goals, researchers report.

medwireNews top story

Heart failure poses greatest CV mortality risk after type 2 diabetes diagnosis

Chalkboard image of patient with heart failure

Real-world study findings suggest that heart failure is associated with the greatest increase in mortality risk when compared with other cardiovascular and renal complications among people with newly diagnosed type 2 diabetes.

ADA 2020

DPPOS: No change to cancer risk with long-term metformin use

Tablet device showing the chemical structure of Metformin

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.

medwireNews

01-08-2021 | Ketoacidosis | News

DKA predictors could facilitate targeted SGLT2 inhibitor use in type 1 diabetes

Increased BMI and insulin resistance are important predictors of diabetic ketoacidosis risk among people with type 1 diabetes using SGLT2 inhibitors, say the authors of a meta-analysis and meta-regression.

01-05-2021 | Heart failure | News

Support for fluid reduction mechanism underlying SGLT2 inhibitor cardiorenal benefits

The SGLT2 inhibitor empagliflozin reduces estimated extracellular volume and plasma volume in patients who have heart failure with reduced ejection fraction, shows a randomized trial.

12-18-2020 | Dapagliflozin | Highlight | News

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits